Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera.
The pharma giant upped its offer, valuing the startup at up to around $10 billion, Metsera said Friday.
STAT Pharma: The science and business of new drug development






Leave a Reply